uniQure announces successful NASDAQ IPO

Amsterdam, The Netherlands – uniQure, a Gilde Healthcare portfolio company, announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share raising $91.8 million and started trading under the symbol "QURE" on the NASDAQ Global Select Market on February 5, 2014. uniQure has granted the underwriters a 30-day option to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the initial public offering are expected to be approximately $81.9 million.
 
Proceeds of the initial public offering will be used for the commercialization of  Glybera® and further clinical development of uniQure’s product pipeline consisting of gene therapies for the treatment of Hemophilia B, Acute Intermittent Porphyria, Sanfilippo B Syndrome and Parkinson’s Disease.
 
Edwin de Graaf represented Gilde Healthcare on the company’s supervisory board and has worked closely with management to support the company’s corporate development since 2006. In this period the company built a platform to rapidly develop and manufacture gene therapies and received regulatory approval for Glybera®, the first gene therapy approved by the European Commission. 

About uniQure
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. uniQure has developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. The approach is validated by multiple partnerships and the regulatory approval of lead product Glybera®. www.uniqure.com

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.